February 26, 2020 / 1:23 PM / a month ago

BRIEF-Puma Biotechnology Receives U.S. FDA Approval Of Supplemental New Drug Application For Neratinib

Feb 26 (Reuters) - Puma Biotechnology Inc:

* PUMA BIOTECHNOLOGY RECEIVES U.S. FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR NERATINIB TO TREAT HER2-POSITIVE METASTATIC BREAST CANCER

* PUMA BIOTECHNOLOGY INC - EXPECTS TO SEEK APPROVAL OF SECOND INDICATION IN ALL COUNTRIES WHERE NERLYNX IS CURRENTLY APPROVED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below